Atezolizumab

In February 2018, Robert J. Motzer, MD, presented results from the phase 3 IMmotion151 trial at the Genitourinary Cancers Symposium. The highly anticipated findings showed significant promise for the combination of atezolizumab plus bevacizumab in patients with untreated metastatic renal cell carcinoma when compared with the standard treatment of sunitinib. In an interview with Healio, Motzer, who was one of the lead investigators of IMmotion151 and is an attending physician at Memorial Sloan Kettering Cancer Center in New York, spoke in detail about the trial, discussing the catalyst, key findings and what the results may mean for the future of the specialty.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about promising immunotherapeutic approaches currently being studied in small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about advancements in the understanding of the molecular biology of small cell lung cancer.

Healio spoke with Jacob Sands, MD, a medical oncologist at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about treatment options for metastatic small cell lung cancer.